Evaluation of standardized triple intrathecal therapy toxicity in oncohematological pediatric patients
Background The administration of triple intrathecal therapy with methotrexate, cytarabine and a corticosteroid for the prophylaxis and treatment of neoplastic cell infiltration in the central nervous system in hematological malignancies is a widespread practice. There is limited information available about its toxicity profile. Several factors related to intrathecal preparation can affect toxicity. Thus, it was decided to standardize intrathecal chemotherapy, trying to obtain the best toxicity profile. Objective To assess the toxicity of a standardized triple intrathecal chemotherapy in oncohematological pediatric patients and to establish risk factors of toxicity. Setting Oncohematological pediatric unit from a tertiary hospital in Spain. Methods Prospective, descriptive and observational study in which all the administrations of standardized triple intrathecal chemotherapy in pediatric patients were registered. Main outcome measure Toxicity of the intrathecal therapy was recorded and possible risk factors were assessed. Results A total of 269 administrations of triple intrathecal chemotherapy were registered in 41 patients (mean age = 6.6 ± 3.9 years). In 16.7% of the procedures, an adverse event was reported (total number of adverse events = 61). 47.5% were grade 1, 47.5% grade 2 and 4.9% grade 3. The administration of intrathecal chemotherapy inpatient and patient age ≥3 years were risk factors of toxicity in the multivariate analysis. Conclusions The administration of standardized triple intrathecal chemotherapy is related to a low frequency of toxicity and most of the adverse events registered were mild/moderate. The detection of adverse effects was significantly greater in children with age greater than or equal to three years and in hospitalized patients.
KeywordsDrug toxicity Factors Hematological neoplasms Intrathecal chemotherapy Pediatrics Risk Spain Standardization
This study had no special source of funding.
Conflicts of interest
The authors have no conflicts of interest to disclose.
- 3.Matloub Y, Lindemulder S, Gaynon PS, Sather H, La M, Broxson E, et al. Intrathecal triple therapy decreases central nervous system relapse but fails to improve event free survival when compared with intrathecal methotrexate: results of the Children’s Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children’s Oncology Group. Blood. 2006;108:1165–73.CrossRefPubMedPubMedCentralGoogle Scholar
- 10.de Lemos ML, Monfared S, Denyssevych T, Hamata L, Jennings S, Thiessen B, et al. Evaluation of osmolality and pH of various concentrations of methotrexate, cytarabine, and thiotepa prepared in normal saline, sterile water for injection, and lactated Ringer’s solution for intrathecal administration. J Oncol Pharm Pract. 2009;15:45–52.CrossRefPubMedGoogle Scholar
- 12.Pui CH; American Society of Hematology. Central nervous system disease in acute lymphoblastic leukemia: prophylaxis and treatment. Hematology. 2006;1:142–6.Google Scholar
- 13.American Society of Health-System Pharmacists. AHFS drug information. Bethesda: American Society of Health-System Pharmacists (ASHP) Inc; 2008. ISBN 978-1-58528-206-7.Google Scholar
- 14.Ortega JJ, Ribera JM, Oriol A, Bastida P, González ME, Calvo C, et al. Early and delayed consolidation chemotherapy significantly improves the outcome of children with intermediate-risk acute lymphoblastic leukemia. Final results of the prospective randomized PETHEMAALL-89 TRIAL. Haematologica. 2001;86:586–95.PubMedGoogle Scholar
- 16.Treatment of leptomeningeal metastases. Uptodate 2014 [cited 2016 Oct 10]. http://www.uptodate.com/contents/treatment-ofleptomeningeal-metastases-carcinomatousmeningitis?source=search_result&search=treatment+of+leptomeningeal+metastases&selectedTitle=1%7E54.
- 17.Giebel S, Krawczyk-Kulis M, Mczyk-Cioch M, Czyz A, Lech-Maranda E, Piatkowska-Jakubas B, et al. Prophylaxis and therapy of central nervous system involvement in adult acute lymphoblastic leukemia: recommendations of the Polish Adult Leukemia Group. Pol Arch Med Wewn. 2008;118:356–61.PubMedGoogle Scholar
- 18.Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0. National Cancer Institute 2013 [cited 2016 Sep 11]. http://www.evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5×11.pdf.
- 23.Mahoney DH Jr, Shuster JJ, Nitschke R, Lauer SJ, Steuber CP, Winick N, et al. Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy: a Pediatric Oncology Group study. J Clin Oncol. 1998;16:1712–22.PubMedGoogle Scholar